Integris Health has raised primary capital from a consortium of prominent investors, including Mukul Agarwal and India SME Fund. The funding will enable the company to expand into multiple therapeutic areas such as in-vitro diagnostics and laboratory solutions through strategic acquisitions and in-house product development initiatives.
The investment marks a significant milestone in Integris Health's journey to becoming one of India’s largest and most diversified med-tech players. In 2024, the company appointed Probir Das as CEO to steer its growth strategy. Integris plans to list publicly by the end of 2025 and has already commenced preparations for its initial public offering (IPO).
Avnish Mehra, Vice Chairman of Everstone Capital, commented: "Integris Health's growth trajectory reflects our commitment to building scalable healthcare platforms. This funding, combined with the company’s proven product development capabilities, consistent organic growth, and acquisition track record, reinforces its position as a transformative med-tech devices business serving hospitals and laboratories globally."
Gurmit Singh Chugh, Co-Founder and Chairman of Integris Health, remarked: "The Indian med-tech devices industry is experiencing unprecedented growth, akin to the transformative opportunities witnessed in the Indian pharmaceutical sector during the early 2000s. Integris Health is poised to lead this global evolution, leveraging cutting-edge R&D, strategic partnerships, robust distribution capabilities, and the cost-efficiency of Indian manufacturing."
Probir Das, CEO of Integris Health, added: “The interest and support from prominent investors reflect confidence in our vision to create India’s leading med-tech devices business. As we prepare for our IPO, we remain committed to building a diversified business. This market, particularly in developing economies, is poised for significant growth due to low penetration levels, and Integris is well-positioned to capitalise on this opportunity.”
